Meeting
2023 ASCO Annual Meeting
Association of host immune signatures with response to immunotherapy-based regimens in patients with metastatic renal cell carcinoma (mRCC).
Authors
Eddy Saad
Dana-Farber Cancer Institute, Boston, MA
Eddy Saad , Chris Labaki , Renee Maria Saliby , Li Song , Ziad Bakouny , Wenting Pan , McKenzy Wall , Gwo-Shu Mary Lee , David A. Braun , Xiaole Shirley Liu , Toni K. Choueiri
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Genitourinary Cancer—Kidney and Bladder
Track
Genitourinary Cancer—Kidney and Bladder
Sub Track
Kidney Cancer
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 4550)
DOI
10.1200/JCO.2023.41.16_suppl.4550
Abstract #
4550
Poster Bd #
42
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Annual Meeting
Pan-cancer B- and T-cell transcriptome analysis of CXCL13 as a predictive marker for immune checkpoint inhibitor response.
First Author: Yu Fujiwara
Poster
2024 ASCO Genitourinary Cancers Symposium
Multi-omic characterization of acquired resistance to immune checkpoint inhibitors in patients with metastatic renal cell carcinoma.
First Author: Eddy Saad
Poster
2022 ASCO Annual Meeting
Preventing adverse events in patients with renal cell carcinoma treated with doublet immunotherapy using fecal microbiota transplantation (FMT): Initial results from perform a phase I study.
First Author: Ricardo Fernandes
Poster
2024 ASCO Annual Meeting
Association of napsin A-specific T cell clonotypes with durable clinical benefit to immunotherapy in patients with metastatic NSCLC.
First Author: Natalie J. Miller